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Abstract
Myeloid and plasmacytoid dendritic cells (mDCs, pDCs) are central to the initiation and the regulation of immune
processes in multiple sclerosis (MS). Natalizumab (NTZ) is a humanized monoclonal antibody approved for the treatment
of MS that acts by blocking expression of VLA-4 integrins on the surface of leukocytes. We determined the proportions of
circulating DC subsets and analyzed expression of VLA-4 expression in 6 relapsing-remitting MS patients treated with NTZ
for 1 year. VLA-4 expression levels on pDCs and mDCs decreased significantly during follow-up. In vitro coculture of
peripheral blood mononuclear cells and pDCs, with different doses of NTZ in healthy controls (HC) and MS patients
showed dose-dependent down-regulation of VLA-4 expression levels in both MS patients and HC, and reduced functional
ability to stimulate antigen-specific T-lymphocyte responses. The biological impact of NTZ may in part be attributable to
inhibition of transmigration of circulating DCs into the central nervous system, but also to functional impairment of
interactions between T cells and DC.
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Introduction
Multiple sclerosis (MS) is a multifocal chronic inflammatory
perivascular demyelinating disease of the central nervous system
(CNS) that is thought to be immune-mediated. Inflammatory
infiltrates in MS lesions consist mainly of macrophages, CD8 cells,
CD4 cells, and B cells, all of which play a role in the disease [1]. The
most accepted hypothesis is that peripheral activated self-reactive
lymphocytes invade the CNS through the blood–brain barrier
(BBB) and, together with the resident microglia and/or dendritic
cells (DCs), elicit local CNS immune responses and cause
demyelination and damage to oligodendrocytes and axons [2].
DCs are central to the maintenance of immunological tolerance, as
well as the initiation and regulation of immune responses. DCs, and
plasmacytoid DCs (pDCs) in particular, are found in MS lesions [3]
and are functionally altered in patients with MS [4,5]. Circulating
DCs comprise at least 2 well-characterized subsets, namely myeloid
DCs (mDCs) and pDCs, which are distinguished by their function
and by their reactivity with a panel of monoclonal antibodies.
mDCs are a major subpopulation of blood DCs that are
CD4+Lin2CD11c+CD123dimCD45RO+HLA-DR+. They express
myeloid markers (CD13, CD33) and have a monocytoid appear-
ance. A major subset of mDCs also expresses the CD1c (BDCA-1)
antigen and drives differentiation of T cells into Th1 lymphocytes.
Blood pDCs express a specific CD303 (BDCA-2) marker.
Phenotyping of peripheral BDCA-2+ DCs characterizes these cells
as being CD4+Lin2CD11c2CD123brightCD45RA+ and lacking
myeloid lineage markers. Both DC subsets and the inflammatory
environment in which DCs become activated can influence the type
of T-cell response they elicit and thus contribute to MS lesions. In
addition, both subsets have been found in the cerebrospinal fluid
(CSF) of MS patients, especially during relapses [6,7,8].
Transmigration of immune cells into the CNS is regulated by
chemokines, cytokines, and adhesion molecules on immune cells.
Breakdown of the BBB is well documented in the pathogenesis of
MS [9]. In MS lesions, activated endothelial cells express
abnormally elevated levels of adhesion molecules, including
intercellular adhesion molecule I (ICAM-I) and vascular cell
adhesion molecule I (VCAM-I), and their elevated levels correlate
with the extent of immune cell infiltration. Ligands for these
adhesions molecules, lymphocyte function-associated antigen 1
(LFA-1) and very late antigen 4 (VLA-4) integrins, respectively,
have been identified on perivascular inflammatory cells in MS
lesions [10,11,12]. VLA-4 (CD49d/CD29), the a-4 submember of
the b1 integrin family expressed on most mononuclear hemato-
poietic cells, plays a role in several immunological tasks, including
immune cell trafficking, activation of myeloid cells and naı¨ve T
and B lymphocytes, and differentiation of effector T cells into Th1,
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Th2, or Th17 [13]. Indeed, VLA-4 constitutes an essential part of
the immunological synapse, and binding of VLA-4 provides
costimulatory signals to T cells [14]. LFA-1 (CD11a) mediates cell
adhesion by binding to a family of adhesion molecules, including
ICAM-1, whose expression reflects activation of cells. [15].
Natalizumab (NTZ) is a humanized monoclonal antibody (mAb)
that binds to the a4b1 chain subunit of VLA4 and a4-a4b7
integrins on peripheral immune cells and blocks the interaction of
VLA-4 with its natural vascular ligands (VCAM-I). Both integrins
(VLA-4 and LFA-1) can potentially regulate extravasation of blood
cells into inflamed tissue and differentiation, priming, and
proliferation of T cells. As a consequence, trafficking of leukocytes
through the BBB into the CNS and, therefore, inflammatory MS
processes are attenuated by NTZ [16]. Of particular interest is the
effect of NTZ on DCs, as DCs are increasingly recognized as an
important component in MS pathogenesis [17].
NTZ was approved for treatment of relapsing-remitting MS
(RRMS) based on the results of 2 phase III clinical trials and an
evidence-based review [18,19,20] in which both the relapse rate
and magnetic resonance imaging (MRI) activity were shown to
decrease. The biological effects of NTZ on different immune cell
populations include decreases in the counts of CD4+ and CD8+ T
lymphocytes, CD19+ B cells, and CD138+ plasma cells in CSF;
NTZ is also responsible for decreases in functional surface
expression of a4-integrin in these cells and in the migration
capacity of circulating CD4+ and CD8+ lymphocytes [21,22,23].
NTZ induces the release of immature leukocytes from bone
marrow and increases circulating bone marrow–derived CD34+
cell expression of VLA-4 [24]. However, very little is known about
the effect of NTZ on DCs, which are key cells in immune
homeostasis. To determine whether circulating DCs are affected
by NTZ, we prospectively investigated the circulating proportion
of mDCs and pDCs and their expression of VLA-4 and LFA-1
molecules in RRMS patients before starting treatment with NTZ
(baseline) and after 48 hours, and 1, 3, and 12 months of
treatment. We then compared these data with those of non-active
and non-treated RRMS (MSC) patients and healthy controls
(HC).
Materials and Methods
Patients
We prospectively enrolled 6 patients (4 women, 2 men) with
clinically diagnosed RRMS [25] who were treated with NTZ
because of at least 1 relapse during the previous year on treatment
with another immunomodulatory agent (interferon-b and/or
glatiramer acetate) before receiving NTZ, with a minimum of 9
T2 lesions on cranial MRI or at least the presence of almost 1
active (Gd+) lesion (according to the European Medicine Agency
authorization). A control group was formed from patients with
non-active RRMS who had never received immunomodulatory
therapy (n = 4) and healthy controls HC (n = 10). Relapse was
defined as the appearance of new symptoms or reappearance of 1
or more neurological symptoms that persisted for at least 48 hours
and that had been preceded by at least 30 days of stable or
improved neurological status in the absence of fever or infection.
The annualized relapse rate (ARR) was calculated as the number
of exacerbations per year/number of patients and was assessed in
the year previous to NTZ treatment and during the year of
treatment. Disease severity was scored using Kurtzke’s Expanded
Disability Status Scale (EDSS) [26]. Routine laboratory blood tests
and urinalysis were performed, and adverse events and concom-
itant therapy were monitored. NTZ was administered intrave-
nously at a dose of 300 mg every 4 weeks. Patients were examined
and changes in the EDSS score were recorded during follow-up.
At each visit, we recorded relapses, adverse events, and occurrence
of infections. Peripheral blood samples were obtained at baseline,
48 hours, and at 1, 3, and 12 months after the start of NTZ
therapy. The latter samples were obtained before drug adminis-
tration. Patients were requested to report new symptoms or
adverse events to our clinic and were revaluated. The Ethics
Committee of the hospital approved the protocol, and all subjects
provided their written informed consent.
At enrolment, none of the patients had experienced an acute
relapse or had received corticosteroids for at least 1 month before
and none had received immunosuppressive or immunomodulatory
drugs during the 2 months. None of the patients were treated with
immunomodulatory agents during NTZ treatment. At entry, all
patients were free of signs or symptoms suggestive of immune
compromise or opportunistic infection, based on their clinical
history and the results of a physical examination and laboratory
tests. We excluded patients with other inflammatory or autoim-
mune diseases, any severe systemic illness, or abnormal results in a
routine laboratory investigation (blood chemistry, complete blood
count, C-reactive protein, thyroid function test, anti-nuclear
antibodies, HIV, hepatitis B and C antibodies, and urinalysis). A
single baseline sample was collected from MSC and HC at the
same time as blood was collected from NTZ-treated MS patients.
Evaluation of MRI active images
Weighted MRI scans of the brain were obtained at baseline and
after 6 and 12 months of NTZ. The number of Gd+ lesions was
analyzed using dual echo fast/turbo spin echo sequences providing
scans with proton density–weighted, T1-weighted, and T2-
weighted contrast while the patients were on NTZ. All scans
were performed at 1.5 Tesla. T2-weighted and gadolinium-
enhanced T1-weighted MRI scans were not performed within 4
weeks of corticosteroid treatment. Non-active radiological disease
was defined as no gadolinium-enhancing lesions and no new T2-
hyperintense lesions [27].
Blood sampling and phenotyping of peripheral blood
DCs. Analysis of VLA-4 and LFA-1 expression levels
during therapy with NTZ
Venous blood samples were collected in pre-chilled ethylene-
diamine tetra-acetic acid (EDTA) sterile tubes and processed
within 2 hours of collection. A complete blood count was also
performed. Whole peripheral blood samples (100 mL) were
labelled by direct staining with mAbs and, after incubation, were
lysed with FACS Lysing solution. Expression of a-4 (CD49d [clone
HP2/1, FITC]) and b-1 (CD29, [clone 4B4, FITC]) integrin
subunits were investigated on DCs from Becton Dickinson (BD
Immunocytometry Systems, San Jose´, California, USA).
The mononuclear cell analysis region was analyzed for DC
markers and cell debris, and dead cells were excluded from the
analysis based on scatter signals. mDCs were defined as lineage-
(CD19-CD3-CD14-CD56-CD16-) and HLA-DR+BDCA-1+ cells.
pDCs were defined as Lin-HLA-DR+BDCA-2+CD123+ (IL-3
receptor a-chain). Percentages of each cell subset are expressed
with respect to total mononuclear cells (R1). Cell subsets and the
expression levels of adhesion molecule VLA-4 and LFA-1 subunits
on circulating mDCs and pDCs were acquired and analyzed using
4-colour flow cytometry. Directly conjugated mAbs and FACS
Lysing solution were obtained from Becton Dickinson. Isotype
control mAbs were used to determine background fluorescence
levels. Acquisition and analysis were performed in a FACSort flow
cytometer (Becton Dickinson) using CellQuest and Flow Jo
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software. Fluorescence intensity gains in cellular surface markers
are a measure of surface expression levels of the investigated
molecules of HC and MSC patients, as previously described
[28,29].
Culture assays
We incubated peripheral blood mononuclear cells (PBMCs)
from HC and MS patients treated with increasing amounts of
NTZ. The local ethics committee approved the performance of a
study involving human cells. PBMCs were obtained from HC and
NTZ-treated MS patients at baseline, and in NTZ-treated MS
patients at specific treatment intervals (48 hours, 3-, 6- and 12-
months) by Ficoll density gradient centrifugation. To test the
hypothesis that NTZ modulates DC counts and VLA-4 and LFA-1
expression in vitro, PBMCs were cultured in the presence or
absence of NTZ at 3 different doses (22, 110, and 550 mg/mL,
respectively). We chose a natalizumab concentration of 110 mg/
mL because it represents the mean maximum observed serum
concentration following the repeat intravenous administration of a
300 mg dose of natalizumab to MS patients according to the
pharmacokinetic studies shown in the package insert (Tysabri
(natalizumab) [package insert]. Cambridge, MA: Biogen Idec Inc.;
July 2010.). We then used a curve of comprising one point of 1/5
of 110 (22 mg/mL) and an additional point at 5 times 110
(550 mg/mL). Moreover, 23 mg/ml is considered the mean
average steady-state trough natalizumab concentrations over the
dosing period.
Antigen-specific T-lymphocyte proliferation assay
We purified pDCs using magnetic cell sorting (BDCA-2 cell
isolation kit, MiltenyiBiotec) from freshly drawn whole blood of
HC and NTZ-treated MS patients, obtaining more than 94% cells
with a lin-12CD123highMHC class IIhigh phenotype. pDCs were
cultured in the presence of antigen-specific stimulus (purified
protein derivative [PPD]) (50 IU/mL) or no antigen, and, 4 hours
later, cells were treated with interleukin (IL) 3 (10 ng/mL) and
NTZ at 110 mg/mL for 1 more day to obtain mature pDCs.
Autologous PBMCs were labelled with carboxyfluorescein succi-
nimidyl ester (CFSE). Pulsed mature pDCs were washed, counted,
and adjusted at a DC:T cell ratio of 1:10 in 300-mL final volumes
of medium (RPMI 1640 supplemented with autologous serum).
Assays were performed in triplicate. After 6 days of coculture,
lymphocyte proliferation was assessed using the CFSE dilution
method.
In parallel, we performed proliferation assays in PBMCs
labelled with CFSE that were stimulated or not with PPD
(50 IU/mL) and assessed lymphocyte proliferation using the
CFSE-dilution method at day 6.
Statistical analysis
Descriptive data are presented as mean 6 standard deviation
(SD) and median and interquartile range (IQR). Comparisons
between patients and controls were performed using the non-
parametric Mann-Whitney test and the 2-tailed Fisher exact test,
when necessary. For comparison of paired data at baseline (before
NTZ treatment) and after therapy, we used an analysis of variance
for repeated measures taking into account all the time points and
without assuming a Gaussian distribution (Kruskal-Wallis test) and
Dunn’s multiple comparison test. Differences were considered
statistically significant with p values,0.05 and highly significant
with p,0.01 and p,0.001. All statistical analyses were performed
using SPSS (SPSS, Inc, Chicago, Illinois, USA).
Results
Patient characteristics at the initiation of treatment are
presented in Table 1. The study cohort comprised 6 patients with
RRMS. Mean age was 33.8 years (range, 26–50 years) and mean
disease duration was 8.2 years (range, 2–17). The mean ARR was
2.4 (range, 1–4) in the previous year. The median EDSS score at
study entry was 2.5 (range, 1.5–5.0). The median number of Gd-
enhancing lesions prior to NTZ treatments was 4.5 (range, 0–15).
The median interval between discontinuation of previous
treatment and start of NTZ was 65 days (range, 35–125 days).
All patients were previously on immunomodulatory treatment
with interferon or glatiramer acetate before receiving NTZ, and 2
patients had also received mitoxantrone induction 3 and 4 years
before the immunomodulatory treatment. With respect to the
MSC group, mean age was 34.0 years (range, 18–52 years) and
mean disease duration was 9.6 years (range, 3–25). The mean
ARR was 1.2 (range, 1–2) in the previous year. The median EDSS
score at study entry was 1.2 (range, 0–4). For the HC group, the
mean age was 32.1 years (range, 29–35 years), 30 were women and
2were men.
Clinical efficacy assessment
One patient with very active disease (clinically and on MRI)
suffered an early relapse after the first NTZ dose, as described by
other authors [30]. The patient was treated with intravenous
methylprednisolone 1 g/day for 5 days. Clinical remission was
incomplete. The 5 remaining MS patients were clinically stable at
6 and 12 months. The mean number of Gd-enhancing lesions in
MRI decreased significantly from 4.5 to 0.57 at 12 months of
NTZ. Our data confirm that active MRI findings in RRMS
patients were clearly modified by NTZ treatment. Headache and
fatigue were the most common clinical adverse reactions to NTZ.
Two patients complained of hypersomnia on the day of NTZ
infusion.
In vivo effects of NTZ on DC subset proportions and VLA-
4 and LFA-1 surface integrin expression during follow-up
in MS patients
At baseline (pre-treatment), no statistically significant differences
were observed in VLA-4 and LFA-1 expression on the mDCs
between NTZ-treated MS patients and HC or MSC patients.
Interestingly, proportions of mDCs were higher in NTZ-treated
MS patients at baseline than in HC (p = 0.04) (Table 2). Similarly,
LFA-1 expression on mDCs was lower in NTZ-treated MS
patients than those of HC and MSC patients (Table 2). LFA-1
expression on pDCs was lower in MS patients at baseline (NTZ
and MSC) than in HC (p = 0.06) (Table 2). Analysis of
fluorescence of VLA-4 and LFA-1 on DC subsets during follow-
up samples after short-term therapy (48 h), intermediate therapy
(3 mo), and long-term therapy (12 mo) revealed a statistically
significant decrease in VLA-4 in pDCs and mDCs between
baseline and 48 hours (97.0066.22 vs 13.41631.35 for pDCs and
98.3963.25 vs. 26.22624.19 for mDCs; p = 0.04 both), at 3
months (13.73630.44 for pDCs and 8.58613.99 for mDCs;
p,0.0001 both); and at 12 months (0.2860.51 for pDCs and
14.57619.81 for mDCs; p = 0.003 and 0.004, respectively)
(Table 2). In Fig. 1, the dot-plot shows the in vivo decrease at
48 hours in VLA-4 on pDCs (from 0.82% to 0.45%) after starting
NTZ treatment in a representative patient. No changes in LFA-1
were noted on pDCs, whereas LFA-1 significantly increased on
mDCs at 12 months (17.55616.41 vs. 47.47636.71; p = 0.05)
(Table 2). There was a trend toward a decreasing proportion of
pDCs from baseline to 48 hours (0.4160.18 to 0.3660.18;
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p = 0.08), at 1 month (0.3560.12; p = 0.06), and at 12-months
(0.3260.15; p = 0.06) (Table 2). This finding is of biological
significance despite the small sample size.
We cannot completely rule out the possibility that any lack of
VLA-4 signal could be partly due to the effect of the drug covering
or hiding the antigen and therefore rendering it not completely
detectable by antibody staining. However, in vitro culture
Table 1. Demographic and clinical characteristics of patients with relapsing-remitting multiple sclerosis (n = 6).
Mean age, years (range) 33.8 (26–50)
Mean disease duration, years (range) 8.2 (2–17)
Mean annualized relapse rate (ARR) during the previous year, mean (range) 2.4 (1–4)
Mean EDSS (range) before treatment 2.5 (1.5–5.0)
Gender, female/male 4/2
Number of Gd-enhancing lesions before NTZ 4.5 (0–15)
Definition of relapsing-remitting multiple sclerosis according to Poser et al. [25] ARR = annualized relapse rate. EDSS = Expanded Disability Status Scale (Kurtzke).
doi:10.1371/journal.pone.0034103.t001
Figure 1. Changes in the in vivo expression of VLA-4 on pDCs before and after 48 hours of natalizumab (NTZ) therapy in MS
patients, compared with healthy controls (HC). Isotypic IgG4 control is marked in red. The example shown is representative for data obtained
from the 6 RRMS patients and 10 HC.
doi:10.1371/journal.pone.0034103.g001
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confirmed that, even at high doses of NTZ, we can observe VLA-4
expression levels in HC (Fig. 2) and NTZ-MS patients (Fig. 3).
In vitro decrease in surface expression of VLA-4 on pDCs
from HC and in NTZ-treated MS patient
Based on previous studies, as pDCs are key cells in the
pathophysiology of MS and the subset that changed most
specifically during NTZ treatment, we focused our studies on DCs.
We incubated pDCs from HC and NTZ-treated MS patients at
baseline with increasing amounts of NTZ. We then performed in
vitro cocultures of PPD-stimulated PBMCs with 3 increasing doses
of NTZ (22 [1/5], 110 [1], and 550 [65] mg/mL, respectively) and
antigen-specific stimulus (PPD, 50 IU/mL) in HC and NTZ-
treated MS. We observed that, in the presence of NTZ, pDCs
displayed down-regulation of VLA-4 (83.7% to 62.5% and to
67.2%), respectively (mean of 3 independent analyses) in HC in a
dose-dependent manner (day 6) (Fig. 2) (n = 3). However, in MS
patients at baseline, in vitro VLA-4 expression on pDCs decreased
uniformly (35% and 59%) in the 3 MS patients tested after
administration of low NTZ doses (22 mg/mL n = 3), while higher
NTZ doses were not able to further down-modulate VLA-4
expression with respect to PPD-stimulated PBMCs alone,
suggesting a saturation effect (data not shown).
In vitro VLA-4 expression on unstimulated and PPD-stimulated
pDCs in MS patients was highly up-modulated to 99% in NTZ-
treated MS patients. Again, NTZ at low doses (22 mg/mL) in
PPD-stimulated cultures was able to down-modulate VLA-4
expression on ex vivo pDCs from NTZ-treated MS patients at
baseline, after 48 hours, and after 3 months of therapy (Figure 3).
As shown in Figure 3 (in a representative experiment of 4 MS
patients), the ability to up-modulate VLA-4 expression at day 6 in
cultures of pDCs of MS patients treated for 3 months with NTZ
was diminished from 61.7% to 30.7% at 3 months of therapy. In
samples stimulated with PPD and to which NTZ was added at
48 hours and 3 months of therapy, VLA-4 expression decreased at
a mean of 17% and 67% in 3 patients, respectively (from 97.9% to
81.2% at 48 h and to 32.3% at 3-months, respectively).
NTZ decreases in vitro the functional ability of pDCs to
stimulate CD4+ T-lymphocyte responses and antigen-
specific proliferative responses
We also analyzed the capacity of pDC to induce proliferation of
autologous T lymphocytes at day 6 of culture (CFSE-labelled
autologous PBMCs were cocultured with PPD-treated pDCs at a
pDC:PBMC ratio of 1:10 and low doses of NTZ (22 mg/mL) in
NTZ-treated MS patients at baseline, 48 hours, and 3 months of
NTZ. As shown in a representative experiment involving 4
patients (Figure 4), NTZ-treated pDCs were less able to stimulate
PPD-specific CD4+ T cell proliferation than non–NTZ-treated
pDCs at the 3 time-points, which ranged from ,54%–76%
inhibition of the PPD response in 3 different experiments in NTZ-
treated MS patients. Moreover, VLA4 expression on pDcs is
maximal without stimulus or with IVIG, while it is down-
modulated after NTZ addition (data not shown). This effect was
more marked in pDCs from the samples of the same patients
monitored at 48 hours and 3 months of NTZ treatment (31.90%
and 26.80%) (Figure 4). These results suggest that, in vivo, NTZ
can modulate the ability of DC to induce antigen-specific CD4+
T-cell responses. Therefore, in addition to down-modulation of
adhesion molecules and the subsequent reduced migration
properties of pDCs, immunogenic function may be different.
Our results differ from the study by Niino et al [14], in which in
vitro addition of NTZ at very low doses (0.1 mg/mL), possibly
negligible with respect to the serum NTZ trough concentrations in
MS patients, seem to trigger a co-stimulatory signal, although
increasing concentration resulted in lower enhancement of
proliferation, compatible with our data.
Table 2. Proportions of circulating subsets of DCs (mDCs and pDCs) and their expression of adhesion molecules (VLA-4 and LFA-1)
at baseline and during natalizumab therapy (NTZ = 6) in MS patients, healthy controls (HC = 10), and untreated RRMS controls
(MSC = 4).
HC MSC Baseline NTZ 48 h NTZ 1-mo NTZ 3-mo NTZ 12-mo NTZ
MDCs 0.2760.22 1.0361.03 0.5160.50¥ 0.5560.54 0.6160.50 0.2060.20 0.4560.32
(HLA-DR+ BDCA-1) 0.22 (0.82-0.49) 0.62 (0.35–2.12) 0.40 (0.10–0.89) 0.43 (0.17–0.90) 0.53 (0.28–0.93) 0.15 (0.17–0.42) 0.40 (0.13–0.82)
VLA-4+ mDCs 97.4364.19 96.8266.36 98.3963.25 26.22624.19* 23.80628.32 8.58613.99*** 14.57629.81***
99.55
(95.39–100)
100
(90.46–100)
99.78
(97.21–100)
24.45 (1.20–49.69) 13.37
(0.57–54.18)
3.26 (0–15.71) 1.12 (0.63–25.41)
LFA-1+ mDCs 26.77621.39 36.49628.69 17.55616.41 31.53638.05 37.28639.36 23.02621.05 47.47636.71*
27.74 (
4.53–45.22)
26.82
(15.72–66.92)
13.19
(4.21–30.83)
22.44 (0.49–60.82) 28.84
(3.17–73.11)
22.5 (2.81–40.86) 65.70 (0.80–74.74)
pDCs 0.5360.29 0.5360.06 0.4160.18 0.3660.18 0.3560.12 0.5260.50 0.3260.15
(CD123+HLA-
DR+BDCA-2+)
0.39 (0.32–0.87) 0.53 (0.46–0.59) 0.37 (0.25–0.56) 0.34 (0.22–0.49) 0.32 (0.25–0.49) 0.41 (0.23–0.75) 0.29 (0.18–0.51)
VLA-4+ pDCs 99.4060.74 99.3160.62* 97.0066.22 13.41631.35* 1.4262.27 13.73630.44*** 0.2860.51***
99.54
(99.30–99.86)
99.38
(98.69–99.86)
99.37
(95.28–100)
0.82 (0.34–20.08) 0.52 (0.19–2.46) 1.47 (0.27–21.3) 0.00 (0.00–0.64)
LFA-1+ pDCs 9.6468.23 1.9561.16 2.2761.62 4.8869.43 2.8363.59 4.3767.71 3.0563.08
9.36 (1.21–18.49) 1.73 (1.00–3.1) 1.75 (0.87–3.95) 1.26 (0.69–7.32) 1.4 (0.28–5.48) 1.58 (0.43–6.89) 1.92 (1.37–5.3)
Data are presented as mean6 standard deviation (SD), median (IQR). *Sig. (2-tailed) with respect to baseline by Wilcoxon Signed Ranks Test. ¥Sig. (2-tailed) with respect
to healthy controls by Mann-Whitney U Test. *p,0.05; **p,0.01; ***p,0.001
doi:10.1371/journal.pone.0034103.t002
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Discussion
We performed a prospective real-life observational 1-year study
in a small series of RRMS patients treated with NTZ. Despite the
small sample size, we show that NTZ induces a marked in vivo and
in vitro decrease in surface expression of VLA-4 on pDCs and
mDCs in the long term, a trend towards decreased pDCs
proportions, and functional impairment of the interactions
between T cells and pDCs.
Considering that DCs are the most potent APCs and play a
critical role in promoting primary T- responses by bridging the
gap between the pathogenesis of MS and CNS immunosurveil-
lance, modifications after treatment with NTZ might provide
important information about its beneficial effects on active MS.
Immunohistochemical studies have demonstrated that resident
and migrated DCs exist within the human CNS at the level of the
meninges, choroid plexus, and vasculature [31,32].
The most accepted hypothesis for the pathophysiology of MS is
that CD4+ T cells are primed in the periphery and then enter the
CNS. In the perivascular space, they encounter myelin antigen
expressed by local APCs, such as microglia and DCs. Integrins on
DCs, in particular VLA-4 and LFA-1, can potentially regulate
endothelial extravasation, including trafficking across the BBB into
the CNS, and differentiation, priming, and proliferation of
Figure 2. Dose-dependent down-modulation of VLA-4 expression on pDCs in vitro after 6 days of culture of PBMCs from healthy
controls with 3 different doses of natalizumab (NTZ)—22 (61/5), 110 (16), and 550 mg/mL (56), respectively—and antigen-specific
stimulus (PPD, 50 IU/mL). The case shown is representative of 3 independent experiments. Isotypic IgG4 control is marked in red. These results
were not reproduced in the MS patients tested (n = 3).
doi:10.1371/journal.pone.0034103.g002
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immune cells both outside and inside the CNS. This finding may
have implications for the pathogenesis of MS. Thus, local
micromilieu signals at the level of the CNS determine functional
differentiation in T cells driven by DCs, ranging from immunos-
timulatory responses to tolerogenic DC responses [33,34,35].
Importantly, we observed a decrease in the proportions of total
pDCs (BDCA-2+HLA-DR+CD123+) at 12 months of therapy with
NTZ.
The question of whether the therapeutic effects of NTZ in MS
are mediated by inhibition of migration of DCs into the CNS or
into other lymphoid tissues remains speculative. We hypothesize
that migration of APCs, including DCs, and their expression of
VLA-4 integrin molecules across the BBB into the CNS is critical
for the initiation, local re-stimulation, and amplification of CD4+
and CD8+ T-cell-mediated immunity in the CNS [30]. CNS DCs
may be key players in the control of local maintenance and
amplification of T cell–mediated immunity. Indeed, NTZ might
block the entry of activated DCs into the CNS by inhibiting the
VLA-4 pathway—but not the LFA-1 pathway—in a similar way
to other activated immune cells. Consequently, our data suggest a
subsequent reduced presentation of self and foreign antigens by
DCs to T in lymphoid tissues and locally within the CNS, where
autoreactive lymphocytes were reactivated. Decreased entry of
DCs and autoreactive immune cells into the CNS in RRMS
patients receiving NTZ treatment may provide additional
beneficial effects of NTZ leading to a decrease in MS activity
[19], as revealed by our clinical and MRI findings. Conversely,
under specific but as yet undefined circumstances, NTZ could
facilitate the occurrence of PML or asymptomatic reactivation of
JC virus [36]. According to this hypothesis, a recent study [37] of
PML in an NZT-treated MS patient found lower numbers of DCs
and CD4+ T cells in the cerebral perivascular spaces than in brain
tissue from control patients with non-neurological diseases,
patients with MS not treated with NTZ, and patients with PML
not associated with NTZ therapy. The reason why some MS
patients develop PML is unknown, but the immune competence of
CD4+ and CD8+ T cells has been shown to be critical for control
of JC virus infection. Thus, inefficient immune surveillance of the
CNS by immune cells could favor the replication of latent JC virus
in the CNS and, potentially, the clinical manifestation of its
Figure 3. In vitro effect of natalizumab (NTZ) on VLA-4 expression on pDCs after 6 days of culture of PBMCs in the presence of
antigen-specific stimulus (PPD) in NTZ-treated MS patients at different time-points (baseline, at 48 hours, and at 3 months). In vitro,
VLA-4 expression on the surface of pDCs was greatly enhanced at day 6 with/without PPD, while NTZ was able to down-modulate it in NTZ-treated
MS patients. In vitro, we observed that the enhanced expression of VLA-4 on pDCs was diminished in NTZ-treated MS patients more markedly after 3
months of therapy and that their pDCs were more sensitive in vitro to the VLA-4 down-modulating effects of NTZ after therapy. Isotypic IgG4 control
is marked in red.
doi:10.1371/journal.pone.0034103.g003
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infection [38,39]. In this scenario, a decrease in the presentation of
antigens such as pDCs, which are capable of producing large
amounts of type 1 interferons, could have an important role in the
pathogenesis of conditions such as viral infection and autoimmune
diseases (eg, MS). In MS, circulating pDCs show reduced
production of IL-6 and IL-10 in response to herpes simplex virus
type I, implying that their response to viral exposure could be
impaired in MS [40]. Similarly, this mechanism could favor JC
viral pathogenicity of the brain of NZT-treated MS patients with
PML. Indeed, JC virus DNA has been found in oligodendrocytes
and astrocytes in various regions of the normal brain. These
findings suggest that JC virus has access to the brain in
immunocompetent subjects. In the setting of marked immuno-
suppression, it is conceivable that resident virus may induce
cytolysis in oligodendrocytes in some MS patients as a result of
NTZ-impaired immune surveillance [41]). These effects on DCs
are compounded by the effects of NTZ on CD4+ and CD8+ T
cells, which also express the VLA-4 molecule.
In conclusion, although our cohort is small, this pilot study
provides biologically significant original data that enable us to
draw the following conclusions. First, in MS patients, circulating
mDCs and pDCs express VLA-4 and LFA-1. Second, we observed
a trend towards decreased proportions of circulating pDCs after
treatment with NTZ, as well as decreased expression of VLA-4 on
mDCs and pDCs. Third, functional impairment of the interaction
between DCs and T cells during treatment with NTZ represents a
potentially new therapeutic approach in MS. These data could
point to a further mechanism of action for NTZ, and this may
have significant implications for immune responses to self and
non-self antigens both inside and outside the CNS and may thus
provide additional clues for our understanding of the beneficial
effects of NTZ. Further studies are needed to confirm our data and
to ascertain whether NTZ also affects other functions of DCs. We
suggest that monitoring clinical and MRI activity in patients with
MS, together with analysis of immunological data, can help us to
better understand the beneficial or potentially hazardous effects of
NTZ in MS patients.
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Figure 4. Effect of natalizumab (NTZ) on the immunogenic function of pDCs. CFSE-labelled autologous T lymphocytes from the same
patient before NTZ treatment (baseline), at 48 hours, and at 3 months of NTZ therapy were cocultured with PPD-treated pDCs at a pDC:PBMC ratio of
1:10. After 6 days, lymphocytes were harvested, and the percentages of proliferating T cells (CFSElow) were calculated. In vitro, NTZ induced reduced
CD4+ T-lymphocyte proliferation in PPD-specific responses in 4 individual NTZ-MS patients. The proliferative responses were weaker when we used
pDCs from the same patients after 48 hours and 3 months of treatment with respect to baseline, suggesting an ongoing progressive functional
impairment.
doi:10.1371/journal.pone.0034103.g004
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